Talis Biomedical (TLIS)
(Real Time Quote from BATS)
$8.50 USD
-0.30 (-3.41%)
Updated Jun 26, 2024 02:48 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
TLIS 8.50 -0.30(-3.41%)
Will TLIS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TLIS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TLIS
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
TLIS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
Other News for TLIS
Tracking David Einhorn's Greenlight Capital Portfolio - Q1 2024 Update
TLIS Stock Earnings: Talis Biomedical Reported Results for Q1 2024
Talis: Q1 Earnings Snapshot
Talis Biomedical Secures Interim CFO Amidst Corporate Changes
TLIS Stock Earnings: Talis Biomedical Reported Results for Q4 2023